New hope for hard-to-treat brain lymphoma: drug combo enters human trials
NCT ID NCT06552559
First seen Apr 24, 2026 · Last updated Jun 13, 2026 · Updated 10 times
Summary
This study tests a new drug, selinexor, added to standard chemotherapy for people with a type of blood cancer (B-cell lymphoma) that has come back or not responded to treatment and has spread to the brain. The goal is to see if the combination is safe and works better than current options. About 37 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Cancer Research Institute
RECRUITINGSeoul, 135-710, South Korea
Contact Email: •••••@•••••
-
Samsung Medical Center
RECRUITINGSeoul, 135-710, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.